Entering the small molecule business in 1995, Dr. Ivashchenko has turned it into the advanced privately owned Drug Discovery and Development center in Russia. ChemRar group has seed-financed or spin-out a number of biotech companies involved in medicine’s research from basic science discovery to the development of new drugs in Oncology, CNS, Virology, incl. HIV, drug formulation and production. He also was a government advisor to the Pharma 2020 program and one of Key Opinion Leaders on industrial policy of Russia’s Pharma Industry. Dr. Ivashchenko is a co-founder and one of initiators of creation of the Biopharmaceutical cluster «Northern» based on MIPT, Fund of development of Phystech-lyceum and phystech-schools, conducts active public, scientific and implementation work within strategy «PHYSTECH XXI» for development of a modern technopolis round MIPT.
Andrey Ivashchenko is a member of various public and government organizations, such as Advisory Council at the Government of the Russian Federation, Advisory Council at Ministry of Industry and Trade of RF on development of pharmaceutical industry, the Subcommittee at the Government commission for protection of public health, a member of the Supervisory Board of the Fund for Assistance to Small Innovative Enterprises in the scientific and technical area of “Skolkovo” fund, the member of Advisory council on development of biotechnologies, pharmaceutical and the medical industry at the Russian State Duma Committee on Industry etc.
In 2015 Andrey Ivashchenko headed NeuroNet «Market» group of designing and assembling of NeuroNet roadmap of the National Technological Initiative (NTI). Professor Ivashchenko has authored and coauthored more than 50 certificates and patents, over 150 scientific publications in Russia and abroad, more than 1000 international deals (USA, Europe, Japan).
Dmitry Kravchenko has more than 25 years of experience in the pharmaceutical and life sciences industries. After graduation with honors from the Chemical Engineering Department of the Mendeleev Chemical Technology University where he specialized in Chemical technology of synthetic biologically active substances, he worked as a researcher, then senior researcher in the Immunomodulators laboratory at the Gerontology Research Institute of the Ministry of Health of the Russian Federation. In 1996 he was an intern at the US Marshall State University, Minnesota. Dr. Kravchenko joined ChemRar Group of Companies in 1999 as a head of the Organic Synthesis Department at Contact Service LLC. Since March 2003 he has held the position of General Director of JSC Chemical Diversity Research Institute – a member of the ChemRar Group with over 200 employees engaged in research and development in the field of pharmacology. Dr. Kravchenko is an author and co-author of over 100 scientific publications and patents.
Nikolay is an entrepreneur and angel investor with more than 15 years of experience in venture capital, focussing on investment opportunities in innovation or commercialization in the fields of biotechnology, pharmaceuticals, medical devices and in vitro diagnostics.
Nikolay has extensive experience in developing strategic, tactical and operational business plans, venture capital transactions and strategic financial management. Having held multiple management positions, he has a solid track record in transforming businesses. Currently supports ChemRar portfolio companies as well as identifies potential new ones.
Master’s degree in Finance at Stockholm University in 2005.
More than 12 years of corporate governance experience in the chemical and pharmaceutical industry. Monitoring of financial transactions and strategic partnership issues.
Since 1998, Irina Tyrnova has been holding key positions at ChemRar Group related to marketing, sales and business development in the international drug research and development projects.
In 2009, Irina was appointed the General Director of Viriom, where she led a project on the development, registration and market launch of a next-generation drug against HIV.
From 2017 to 2023, Irina Tyrnova headed the ChemRar Research Institute, a leading contract research organization for the development of innovative drugs in Russia.
Since 2021, Irina has been the General Director of Chromis, a joint venture of the Russian Direct Investment Fund (RDIF) and ChemRar Group for the development and market launch of “Avifavir” — the first medicinal product against COVID-19 in Russia and the world. As a Member of the Board of Directors at ChemRar Group, she also supervises the exports of the Company’s medicinal products.